A detailed history of High Vista Strategies LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, High Vista Strategies LLC holds 8,981 shares of CLDX stock, worth $211,502. This represents 0.12% of its overall portfolio holdings.

Number of Shares
8,981
Previous 9,627 6.71%
Holding current value
$211,502
Previous $356,000 14.33%
% of portfolio
0.12%
Previous 0.14%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$32.06 - $44.56 $20,710 - $28,785
-646 Reduced 6.71%
8,981 $305,000
Q2 2024

Aug 14, 2024

BUY
$32.76 - $42.56 $315,380 - $409,725
9,627 New
9,627 $356,000
Q3 2023

Nov 14, 2023

SELL
$25.45 - $37.46 $184,767 - $271,959
-7,260 Reduced 29.34%
17,482 $481,000
Q4 2022

Feb 14, 2023

SELL
$27.78 - $45.38 $19,001 - $31,039
-684 Reduced 2.69%
24,742 $1.1 Million
Q3 2022

Nov 14, 2022

BUY
$22.7 - $37.57 $68,417 - $113,235
3,014 Added 13.45%
25,426 $715,000
Q2 2022

Aug 15, 2022

SELL
$20.5 - $37.33 $68,183 - $124,159
-3,326 Reduced 12.92%
22,412 $604,000
Q1 2022

May 16, 2022

SELL
$27.64 - $39.32 $113,821 - $161,919
-4,118 Reduced 13.79%
25,738 $877,000
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $49,595 - $78,215
1,390 Added 4.88%
29,856 $1.15 Million
Q3 2021

Nov 15, 2021

SELL
$28.95 - $55.99 $157,111 - $303,857
-5,427 Reduced 16.01%
28,466 $1.54 Million
Q2 2021

Aug 16, 2021

BUY
$20.71 - $35.37 $19,736 - $33,707
953 Added 2.89%
33,893 $1.13 Million
Q1 2021

May 17, 2021

SELL
$16.19 - $29.91 $273,853 - $505,927
-16,915 Reduced 33.93%
32,940 $678,000
Q4 2020

Feb 16, 2021

BUY
$14.99 - $22.75 $75,339 - $114,341
5,026 Added 11.21%
49,855 $873,000
Q3 2020

Nov 16, 2020

BUY
$9.65 - $15.19 $432,599 - $680,952
44,829 New
44,829 $665,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.1B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track High Vista Strategies LLC Portfolio

Follow High Vista Strategies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Vista Strategies LLC with notifications on news.